developing therapeutic cancer vaccines


Press releases

Press releases

ViciniVax announces first patient treated in Phase I study with immunotherapy Vvax001 for HPV-related precancers and cancer
February 03, 2017

Phase I study initiated with Vvax001 in patients with a history of cervical intraepithelial neoplasia (CIN) 2 and 3 and cervical cancer.

Meet us at Cell Therapy Manufacturing and Gene Therapy Congress 2016
November 04, 2016

J.Meulenberg, CEO of ViciniVax, will present at the 2016 Cell Therapy Manufacturing and Gene Therapy Congress, from November 28-29 in Amsterdam, The Netherlands.

Meet us at Bio US 2016
June 03, 2016

J.Meulenberg, CEO of ViciniVax, attends the 2016 BIO International convention, from June 6-9 in San Francisco 

Start of non-clinical safety studies
April 03, 2014

ViciniVax initiates Vvax001 non-clinical safety studies in UK and US.

Intravacc and ViciniVax sign license agreement to advance the development of a novel vaccine against cervical cancer
March 13, 2013
Grote stap van muis naar mens (Dutch article in RABObank magazine)
December 04, 2012
Closing of first financing round
July 01, 2011

ViciniVax closes first financing round and secures development of lead product until Phase 2a